Biochemical and molecular mechanisms of action of bisphosphonates

Michael J Rogers, Julie C Crockett, Fraser Coxon, Jukka Mönkkönen

Research output: Contribution to journalArticle

287 Citations (Scopus)

Abstract

This review describes the key discoveries over the last 15 years that have led to a clearer understanding of the molecular mechanisms by which bisphosphonate drugs inhibit bone resorption. Once released from bone mineral surfaces during bone resorption, these agents accumulate intracellularly in osteoclasts. Simple bisphosphonates such as clodronate are incorporated into non-hydrolysable analogues of adenosine triphosphate, which induce osteoclast apoptosis. The considerably more potent nitrogen-containing bisphosphonates are not metabolised but potently inhibit farnesyl pyrophosphate (FPP) synthase, a key enzyme of the mevalonate pathway. This prevents the synthesis of isoprenoid lipids necessary for the post-translational prenylation of small GTPases, thereby disrupting the subcellular localisation and normal function of these essential signalling proteins. Inhibition of FPP synthase also results in the accumulation of the upstream metabolite isopentenyl diphosphate, which is incorporated into the toxic nucleotide metabolite ApppI. Together, these properties explain the ability of bisphosphonate drugs to inhibit bone resorption by disrupting osteoclast function and survival. These discoveries are also giving insights into some of the adverse effects of bisphosphonates, such as the acute phase reaction that is triggered by inhibition of FPP synthase in peripheral blood monocytes. This article is part of a Special Issue entitled Bisphosphonates.
Original languageEnglish
Pages (from-to)34-41
Number of pages8
JournalBone
Volume49
Issue number1
Early online date25 Nov 2010
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Diphosphonates
Osteoclasts
Bone Resorption
Clodronic Acid
Prenylation
Mevalonic Acid
Acute-Phase Reaction
Monomeric GTP-Binding Proteins
Poisons
Terpenes
Pharmaceutical Preparations
Minerals
Monocytes
Nitrogen
Adenosine Triphosphate
Apoptosis
Lipids
Bone and Bones
Enzymes
farnesyl pyrophosphate

Keywords

  • Prenylation
  • GTPase
  • Mevalonate
  • FPP
  • GGPP
  • IPP
  • ApppI
  • Cholesterol

Cite this

Rogers, M. J., Crockett, J. C., Coxon, F., & Mönkkönen, J. (2011). Biochemical and molecular mechanisms of action of bisphosphonates. Bone, 49(1), 34-41. https://doi.org/10.1016/j.bone.2010.11.008

Biochemical and molecular mechanisms of action of bisphosphonates. / Rogers, Michael J; Crockett, Julie C; Coxon, Fraser; Mönkkönen, Jukka.

In: Bone, Vol. 49, No. 1, 07.2011, p. 34-41.

Research output: Contribution to journalArticle

Rogers, MJ, Crockett, JC, Coxon, F & Mönkkönen, J 2011, 'Biochemical and molecular mechanisms of action of bisphosphonates', Bone, vol. 49, no. 1, pp. 34-41. https://doi.org/10.1016/j.bone.2010.11.008
Rogers MJ, Crockett JC, Coxon F, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011 Jul;49(1):34-41. https://doi.org/10.1016/j.bone.2010.11.008
Rogers, Michael J ; Crockett, Julie C ; Coxon, Fraser ; Mönkkönen, Jukka. / Biochemical and molecular mechanisms of action of bisphosphonates. In: Bone. 2011 ; Vol. 49, No. 1. pp. 34-41.
@article{3d15d0f6b7e34d078d7d50dd9a5f3d6d,
title = "Biochemical and molecular mechanisms of action of bisphosphonates",
abstract = "This review describes the key discoveries over the last 15 years that have led to a clearer understanding of the molecular mechanisms by which bisphosphonate drugs inhibit bone resorption. Once released from bone mineral surfaces during bone resorption, these agents accumulate intracellularly in osteoclasts. Simple bisphosphonates such as clodronate are incorporated into non-hydrolysable analogues of adenosine triphosphate, which induce osteoclast apoptosis. The considerably more potent nitrogen-containing bisphosphonates are not metabolised but potently inhibit farnesyl pyrophosphate (FPP) synthase, a key enzyme of the mevalonate pathway. This prevents the synthesis of isoprenoid lipids necessary for the post-translational prenylation of small GTPases, thereby disrupting the subcellular localisation and normal function of these essential signalling proteins. Inhibition of FPP synthase also results in the accumulation of the upstream metabolite isopentenyl diphosphate, which is incorporated into the toxic nucleotide metabolite ApppI. Together, these properties explain the ability of bisphosphonate drugs to inhibit bone resorption by disrupting osteoclast function and survival. These discoveries are also giving insights into some of the adverse effects of bisphosphonates, such as the acute phase reaction that is triggered by inhibition of FPP synthase in peripheral blood monocytes. This article is part of a Special Issue entitled Bisphosphonates.",
keywords = "Prenylation, GTPase, Mevalonate, FPP, GGPP, IPP , ApppI , Cholesterol",
author = "Rogers, {Michael J} and Crockett, {Julie C} and Fraser Coxon and Jukka M{\"o}nkk{\"o}nen",
note = "Copyright {\circledC} 2010 Elsevier Inc. All rights reserved.",
year = "2011",
month = "7",
doi = "10.1016/j.bone.2010.11.008",
language = "English",
volume = "49",
pages = "34--41",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Biochemical and molecular mechanisms of action of bisphosphonates

AU - Rogers, Michael J

AU - Crockett, Julie C

AU - Coxon, Fraser

AU - Mönkkönen, Jukka

N1 - Copyright © 2010 Elsevier Inc. All rights reserved.

PY - 2011/7

Y1 - 2011/7

N2 - This review describes the key discoveries over the last 15 years that have led to a clearer understanding of the molecular mechanisms by which bisphosphonate drugs inhibit bone resorption. Once released from bone mineral surfaces during bone resorption, these agents accumulate intracellularly in osteoclasts. Simple bisphosphonates such as clodronate are incorporated into non-hydrolysable analogues of adenosine triphosphate, which induce osteoclast apoptosis. The considerably more potent nitrogen-containing bisphosphonates are not metabolised but potently inhibit farnesyl pyrophosphate (FPP) synthase, a key enzyme of the mevalonate pathway. This prevents the synthesis of isoprenoid lipids necessary for the post-translational prenylation of small GTPases, thereby disrupting the subcellular localisation and normal function of these essential signalling proteins. Inhibition of FPP synthase also results in the accumulation of the upstream metabolite isopentenyl diphosphate, which is incorporated into the toxic nucleotide metabolite ApppI. Together, these properties explain the ability of bisphosphonate drugs to inhibit bone resorption by disrupting osteoclast function and survival. These discoveries are also giving insights into some of the adverse effects of bisphosphonates, such as the acute phase reaction that is triggered by inhibition of FPP synthase in peripheral blood monocytes. This article is part of a Special Issue entitled Bisphosphonates.

AB - This review describes the key discoveries over the last 15 years that have led to a clearer understanding of the molecular mechanisms by which bisphosphonate drugs inhibit bone resorption. Once released from bone mineral surfaces during bone resorption, these agents accumulate intracellularly in osteoclasts. Simple bisphosphonates such as clodronate are incorporated into non-hydrolysable analogues of adenosine triphosphate, which induce osteoclast apoptosis. The considerably more potent nitrogen-containing bisphosphonates are not metabolised but potently inhibit farnesyl pyrophosphate (FPP) synthase, a key enzyme of the mevalonate pathway. This prevents the synthesis of isoprenoid lipids necessary for the post-translational prenylation of small GTPases, thereby disrupting the subcellular localisation and normal function of these essential signalling proteins. Inhibition of FPP synthase also results in the accumulation of the upstream metabolite isopentenyl diphosphate, which is incorporated into the toxic nucleotide metabolite ApppI. Together, these properties explain the ability of bisphosphonate drugs to inhibit bone resorption by disrupting osteoclast function and survival. These discoveries are also giving insights into some of the adverse effects of bisphosphonates, such as the acute phase reaction that is triggered by inhibition of FPP synthase in peripheral blood monocytes. This article is part of a Special Issue entitled Bisphosphonates.

KW - Prenylation

KW - GTPase

KW - Mevalonate

KW - FPP

KW - GGPP

KW - IPP

KW - ApppI

KW - Cholesterol

U2 - 10.1016/j.bone.2010.11.008

DO - 10.1016/j.bone.2010.11.008

M3 - Article

C2 - 21111853

VL - 49

SP - 34

EP - 41

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -